Reactivity of a monoclonal antibody with human ovarian carcinoma.

Bast, Robert C.; Feeney, M.; Lazarus, Herbert; Nadler, Lee M.; Colvin, Robert B.; Knapp, Robert C.

doi:10.1172/jci110380

Cited by 1,472 publications

(706 citation statements)

References 36 publications

Supporting

Mentioning

670

Contrasting

Unclassified

Order By: Relevance

“…Slides were then washed with PBS and incubated with normal serum (Vectastain ABC kit, Vector Laboratories, Burlingame, CA, USA) for 30 min for blocking the nonspecific immunostaining. The sections were then incubated with a 1:100 dilution of anti-MUC1 (HMFG-2) 24 or MUC4 (8G7) 23 or MUC16 (OC125) 25 mouse monoclonal antibodies at room temperature for 1 h. To confirm the specificity of the IHC staining, one set of the slides was incubated with PBS without any primary antibody (no antibody control). Slides were washed (3 Â 5 min) with PBS containing 0.05% Tween-20 (PBS-T) and the sections were incubated with biotinylated-secondary antibody for 30 min slides were washed again (3 Â 5 min) with PBS-T before incubation with ABC solution (Vector Laboratories) at room temperature.…”

Section: Immunohistochemistrymentioning

confidence: 99%

Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125)

et al. 2006

View full text Add to dashboard Cite

Mucins are being implicated in diagnosis, prognosis, and as therapeutic targets due to their aberrant expression in a variety of carcinomas. Here, we have analyzed the expression of MUC4 and have compared its potential usefulness in early detection and prognosis of ovarian carcinoma alone and in combination with other mucin antigens, MUC1 and MUC16. Clinical significance of the differential mucin expression was evaluated by grouping the tumor samples in early (stage I and II) and advanced (stage III and IV) stage cases and histological subtypes (serous, mucinous, endometrioid and clear cell). Correlation of these mucins with patient's survival (n ¼ 63) was determined by Kaplan-Meier analysis in order to predict their prognostic value. MUC4 showed significant overexpression in tumor cases (Po0.0001) with highest incidence (92.0%) among all three mucins. A significant overexpression of MUC1 (Po0.018) and MUC16 (Po0.0001) was also observed in 83.0 and 79.0% of tumor samples, respectively. Notably, MUC4 expression was significantly higher (Pr0.004) compared to both MUC1 and MUC16 in early-stage ovarian tumor samples with 100% incidence. In advanced stage ovarian tumors, all the mucins displayed overall comparable expression, nonetheless, MUC4 had highest prevalence (88.0%) compared to MUC1 (84.0%) and MUC16 (81.0%). A combined panel of MUC4 with MUC16 detected 100% of the late-stage tumor cases without compromising the specificity. Among histological subtypes, only MUC4 displayed 100% (n ¼ 5) sensitivity in mucinous ovarian tumors, while MUC1 and MUC16 detected 40 and 20% cases, respectively. The expression of MUC4, however, did not significantly correlate with the survival of the ovarian cancer patient, while a significant correlation of MUC16 with poor prognosis was observed. In conclusion, our study demonstrates that MUC4 could be a potential candidate marker for early diagnosis of epithelial ovarian carcinoma and can be utilized in combination with MUC16 to achieve greater sensitivity for the detection of late-stage tumors.

show abstract

Section: Immunohistochemistrymentioning

confidence: 99%

Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125)

et al. 2006

View full text Add to dashboard Cite

show abstract

“…These epitopes are also detected in fetal coelomic epithelium, muUerian duct remnants, amnion and amniotic fluid. CA 125 antigenic determinants are not found in normal adult ovarian tissues but are associated with epithelial ovarian carcinoma (11)(12)(13)(14)(15)(16)(17).…”

Section: Cancer Antigen 125 (Ca 125)mentioning

confidence: 99%

Application of tumor markers in ovarian malignancies

Malati

Kumari

Yadagiri

2001

Indian J Clin Biochem

View full text Add to dashboard Cite

Ovarian cancer is the fifth leading cause of death in women. The incidence of this malignancy increases in women over the age of 40. The overall five years survival is less than 30%, as most women present with advanced stage disease. Until recently, detection of early stage ovarian cancer has been difficult since it is usually nonpalpable and asymptomatic. The definitive diagnosis of an ovarian mass is a common problem in gynecologic patients with adnexal mass. The routine standard evaluation for adnexal masses includes patient's history, physical examination, ultrasound and histopathological examination. These parameters individually or in combination have little predictive value. The accuracy of diagnostic tools are of immense value and great concern to practicsing Gynecologists and Oncologists. The clinical application of serum concentration of CA 125, AFP and hCG is of great help not only as diagnostic aid but also in monitoring efficacy of any treatment modality like chemotherapy, radiotherapy or surgical resection. Additionally, evaluation of tumor marker concentration helps in predicting early biochemical recurrence and in prognostication in different types of ovarian malignancies. The ability to differentiate a malignant mass from a benign pelvic mass pretherapeutically could be enhanced optimally by additional use of tumor markers such as cancer antigen CA-125, alphafetoprotein and human chorionic gonadotrophin in pre-and postmenopausal women.

show abstract

“…Several antigens have been detected in association with ovarian carcinomas (Donaldson et al, 1980;Bast et al, 1981;Bhattacharya et al, 1982) and of these CA125 has shown the most clinical promise to date Canney et al, 1984). CA 125, a high molecular weight glycoprotein expressed in coelomic epithelium during embryonic development, is defined by a murine monoclonal antibody raised against a serous ovarian carcinoma cell line, OVCA 433.…”

mentioning

confidence: 99%

Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker

Canney¹,

Moore²,

Wilkinson³

et al. 1984

Br J Cancer

304

133

View full text Add to dashboard Cite

Summary Serum CA 125, quantified by an immunoradiometric assay employing the monoclonal antibody OC125 was found to be elevated in 48/58 (83%) of patients with established ovarian cancer. All histological types of carcinoma were antigen positive and there was a positive correlation between the frequency and level of serum CA125 and body burden of tumour. Twenty patients undergoing chemotherapy had serial CA125 estimations following a prospective protocol. Variation in CA125 level reflected disease progression or regression in 21/23 instances. Three of 9 patients tested showed an acute elevation of CA125 in the first week following chemotherapy and this effect predicted a good response to treatment. The natural half-life of CA125 in serum was estimated at -4.8 days, sufficiently short to allow changes in tumour volume to be rapidly reflected by a change in circulating antigen level. Although none of 15 patients with non-Hodgkin lymphoma demonstrated antigen levels outside the normal range, 11/27 patients with non-ovarian adenocarcinoma showed elevated CA125 levels, a specificity of 58% for this latter group. The value of CA125 in the management of ovarian malignancy is discussed.

show abstract

Reactivity of a monoclonal antibody with human ovarian carcinoma.

Cited by 1,472 publications

References 36 publications

Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125)

Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125)

Application of tumor markers in ovarian malignancies

Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker

Contact Info

Product

Resources

About